Peter W. Gout

7.6k total citations · 2 hit papers
99 papers, 5.8k citations indexed

About

Peter W. Gout is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Peter W. Gout has authored 99 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 40 papers in Oncology and 20 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Peter W. Gout's work include Growth Hormone and Insulin-like Growth Factors (19 papers), Amino Acid Enzymes and Metabolism (15 papers) and Prostate Cancer Treatment and Research (12 papers). Peter W. Gout is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (19 papers), Amino Acid Enzymes and Metabolism (15 papers) and Prostate Cancer Treatment and Research (12 papers). Peter W. Gout collaborates with scholars based in Canada, United States and China. Peter W. Gout's co-authors include Yuzhuo Wang, Charles T. Beer, R. L. Noble, Maisie Lo, Lígia Morganti, Eric Ueda, Colin C. Collins, Stephen Yiu Chuen Choi, Henry G. Friesen and Robert P. C. Shiu and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and PLoS ONE.

In The Last Decade

Peter W. Gout

98 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Cystine/Glutamate Antiporter System x _c ⁻ in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities

2012 767 citations Peter W. Gout et al. profile →
A New Sensitive and Specific Bioassay for Lactogenic Hormones: Measurement of Prolactin and Growth Hormone in Human Serum*

1980 503 citations Peter W. Gout, Charles T. Beer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter W. Gout Canada	36	3.2k	1.4k	1.3k	1000	821	99	5.8k
Jørgen Gliemann Denmark	58	5.4k 1.7×	1.6k 1.1×	834 0.6×	555 0.6×	1.1k 1.4×	156	10.7k
Toshiyuki Takeuchi Japan	46	3.9k 1.2×	1.2k 0.8×	1.1k 0.9×	1.2k 1.2×	668 0.8×	178	8.3k
Tullio Florio Italy	57	5.0k 1.6×	1.4k 1.0×	2.9k 2.1×	501 0.5×	1.3k 1.6×	272	10.3k
Ulrich Pfeffer Italy	41	3.6k 1.1×	1.2k 0.8×	1.3k 1.0×	757 0.8×	282 0.3×	143	6.3k
Chris J. Vlahos United States	36	5.8k 1.8×	659 0.5×	928 0.7×	395 0.4×	595 0.7×	68	8.5k
Jean‐Claude Chambard France	34	4.6k 1.5×	1.0k 0.7×	1.2k 0.9×	279 0.3×	521 0.6×	52	7.4k
Markus Wartmann Switzerland	39	3.8k 1.2×	650 0.5×	2.1k 1.6×	680 0.7×	216 0.3×	89	6.9k
Marco Falasca Australia	51	5.4k 1.7×	1.1k 0.8×	2.1k 1.5×	400 0.4×	298 0.4×	183	8.7k
Pirkko Vihko Finland	51	3.2k 1.0×	703 0.5×	1.4k 1.0×	1.5k 1.5×	1.8k 2.1×	179	7.3k
Yoon S. Cho‐Chung United States	43	4.1k 1.3×	620 0.4×	1.9k 1.4×	464 0.5×	394 0.5×	159	6.4k

Countries citing papers authored by Peter W. Gout

Since Specialization

Citations

This map shows the geographic impact of Peter W. Gout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter W. Gout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter W. Gout more than expected).

Fields of papers citing papers by Peter W. Gout

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter W. Gout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter W. Gout. The network helps show where Peter W. Gout may publish in the future.

Co-authorship network of co-authors of Peter W. Gout

This figure shows the co-authorship network connecting the top 25 collaborators of Peter W. Gout. A scholar is included among the top collaborators of Peter W. Gout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter W. Gout. Peter W. Gout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Choi, Stephen Yiu Chuen, et al.. (2019). Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells. Frontiers in Cellular and Infection Microbiology. 9. 25–25. 7 indexed citations

Ci, Xinpei, Jun Hao, Xin Dong, et al.. (2018). Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research. 78(10). 2691–2704. 55 indexed citations

Hao, Jun, Xinpei Ci, Hui Xue, et al.. (2018). Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. European Urology. 73(6). 949–960. 14 indexed citations

Choi, Stephen Yiu Chuen, Hui Xue, Rebecca Wu, et al.. (2016). The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clinical Cancer Research. 22(11). 2721–2733. 79 indexed citations

Shrestha, Raunak, Hui Xue, Yuwei Wang, et al.. (2016). BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research. 23(6). 1542–1551. 25 indexed citations

Lin, Dong, Ladan Fazli, Kuo Yang, et al.. (2013). BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. PLoS ONE. 8(2). e55837–e55837. 30 indexed citations

Watahiki, Akira, Yuwei Wang, James Morris, et al.. (2011). MicroRNAs Associated with Metastatic Prostate Cancer. PLoS ONE. 6(9). e24950–e24950. 171 indexed citations

Stany, Michael P., Vinod Vathipadiekal, Laurent Ozbun, et al.. (2011). Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE. 6(7). e21121–e21121. 74 indexed citations

Lo, Maisie, Victor Ling, Yuzhuo Wang, & Peter W. Gout. (2008). The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. British Journal of Cancer. 99(3). 464–472. 172 indexed citations

10.

Lo, Maisie, Yuzhuo Wang, & Peter W. Gout. (2008). The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. Journal of Cellular Physiology. 215(3). 593–602. 342 indexed citations

11.

Lo, Maisie, Yuwei Wang, Hui Xue, et al.. (2006). Sulfasalazine: Potential use of an old drug for treatment of pancreatic cancer. Cancer Research. 66. 1105–1106. 2 indexed citations

12.

Gout, Peter W., et al.. (2005). Growth arrest by sulfasalazine (SASP) of subrenal capsule prostate cancer xenografts in immuno-deficient mice is coupled to a decrease in the number of tumor-associated macrophages. Cancer Research. 65. 1380–1380. 1 indexed citations

13.

Gout, Peter W., Jun Guan, Yuwei Wang, et al.. (2004). Potential use for sulfasalazine in lung cancer therapy. Cancer Research. 64. 887–887. 1 indexed citations

14.

Lee, Cheng‐Han, Hui Xue, Margaret Sutcliffe, et al.. (2004). Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecologic Oncology. 96(1). 48–55. 70 indexed citations

15.

Ribela, Maria Teresa C.P., Peter W. Gout, & Paolo Bartolini. (2003). Synthesis and chromatographic purification of recombinant human pituitary hormones. Journal of Chromatography B. 790(1-2). 285–316. 16 indexed citations

16.

Butnev, Viktor Y., et al.. (1996). Glycosylated equine prolactin and its carbohydrate moiety. Journal of Protein Chemistry. 15(5). 413–426. 3 indexed citations

17.

Richards, James, et al.. (1990). Inhibition of hormone-stimulated ornithine decarboxylase activity by lithium chloride. Life Sciences. 47(3). 233–240. 9 indexed citations

18.

Gout, Peter W., et al.. (1989). Bioactive Recombinant Methionyl Bovine Prolactin: Structure-Function Studies Using Site-Specific Mutagenesis. Molecular Endocrinology. 3(5). 822–831. 32 indexed citations

19.

Riddick, Daniel H., et al.. (1988). Physicochemical characterization and functional activity of fibroid prolactin produced in cell culture. American Journal of Obstetrics and Gynecology. 158(4). 846–853. 13 indexed citations

20.

Emanuele, Nicholas, John J. Tentler, Thad C. Hagen, et al.. (1987). Extrahypothalamic brain prolactin: characterization and evidence for independence from pituitary prolactin. Brain Research. 421(1-2). 255–262. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact